Showing results (21-30 of 44) with videos related to
Sort By:
Pageof 5
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2024
Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin LymphomaMatthew Mei, Ni-Chun Tsai, Joycelynne Palmer, et al.Clinical Lymphoma|April 10, 2004
Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemiaMichael Keating, Stephen Coutré, Kanti Rai, et al.International Journal of Biological Sciences|July 9, 2021
Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancerThuy Phan, Vu H Nguyen, Ralf Buettner, et al.Cancers|December 9, 2023
POLD1 DEDD Motif Mutation Confers Hypermutation in Endometrial Cancer and Durable Response to PembrolizumabChristina Hsiao Wei, Edward Wenge Wang, Lingzi Ma, et al.Neuromodulation : Journal of the International Neuromodulation Society|August 17, 2023
Multiphase Spinal Cord Stimulation in Participants With Chronic Back or Leg Pain: Results of the BENEFIT-02 Randomized Clinical TrialLeonardo Kapural, Denis G Patterson, Sean Li, et al.Journal of Immunological Sciences|March 30, 2023
Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic ChangesAda Alice Dona, James F Sanchez, Joycelynne M Palmer, et al.Journal of Cellular Physiology|January 10, 2019
The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AMLLe Xuan Truong Nguyen, Estelle Troadec, Arjun Kalvala, et al.Oncoimmunology|October 6, 2018
Daratumumab induces CD38 internalization and impairs myeloma cell adhesionJayeeta Ghose, Domenico Viola, Cesar Terrazas, et al.Breast Cancer Research and Treatment|March 2, 2011
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinibVirginia G Kaklamani, Kalliopi Siziopikou, Denise Scholtens, et al.The Lancet. Haematology|July 27, 2024
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 studyAlex F Herrera, Jasmine Zain, Kerry J Savage, et al.Pageof 5